Rep. Lisa C. McClain (R-MI) Buys ImmunityBio (IBRX) Stock
Rep. Lisa C. McClain bought ImmunityBio shares valued between $1,001 and $15,000 on September 30, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Lisa C. McClain (R-MI) bought between $1,001 and $15,000 of ImmunityBio, Inc. ($IBRX) stock on September 30, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 12, 2026.
Since the trade, $IBRX is up 3.3% after 1 week and down 2.8% to date (from the $9.44 close on Sep 30, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Lisa C. McClain (R)
- Status:
- Member — House
- Party:
- Republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 12, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| ImmunityBio, Inc. ($IBRX) | Buy | Sep 30, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. View the original: STOCK Act disclosure (House Clerk)
IBRX
ImmunityBio, Inc.
Key Points
- On September 30, 2026, Rep. Lisa C. McClain purchased ImmunityBio shares valued between $1,001 and $15,000.
- As of October 16, 2026, ImmunityBio stock trades recently around $9.30, which is below its mean price target of $14.25.
- The company reported a trailing twelve-month revenue of $165.8 million with a year-over-year revenue growth of 93.9%.
Get $IBRX trade alerts by text
We text you when insiders, Congress or big funds trade $IBRX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated ImmunityBio, Inc. alert may contain errors. Disclosures
Rep. Lisa C. McClain bought shares of ImmunityBio, Inc. (IBRX) valued between $1,001 and $15,000 on September 30, 2026. This transaction was disclosed on October 12, 2026, in a periodic transaction report filed under the STOCK Act.
Lisa C. McClain vs. the S&P 500
Hypothetical returns from Lisa C. McClain's disclosed trades, not real profit or advice. How we model this.
Inside Lisa C. McClain's Trade
McClain's purchase adds to her portfolio as she continues to invest in biotechnology. The transaction reflects her interest in ImmunityBio, a company focused on developing immunotherapies for cancer and infectious diseases.
Other Institutional Activity in ImmunityBio
Several large funds have positions in ImmunityBio. Blackrock Inc. holds 34,083,262 shares worth about $312.9 million, having increased its stake by 7,737,693 shares, a 29.4% rise. State Street Corporation has 21,398,438 shares valued at approximately $196.4 million after adding 3,690,363 shares, a 20.8% increase. Vanguard Portfolio Management LLC owns 17,863,911 shares worth about $164.0 million, with a 9.4% increase after buying 1,540,893 shares. Vanguard Capital Management LLC holds 15,691,579 shares valued at about $144.0 million, having increased its stake by 564,249 shares, a 3.7% rise. Shaw D.E. & Co., Inc. reduced its holdings by 1,020,834 shares, now owning 11,551,019 shares worth about $106.0 million, reflecting an 8.1% decrease.
ImmunityBio, Inc. Stock Down 7.2%
As of October 16, 2026, ImmunityBio shares trade recently around $9.30. This price is above its 52-week low of $1.95 but significantly below its 52-week high of $12.43. The stock is currently above its 50-day moving average of $8.47 and its 200-day moving average of $7.52. However, it trades below its mean price target of $14.25, indicating some room for growth according to analysts.
Recent Earnings
ImmunityBio reported trailing twelve-month revenue of $165.8 million, reflecting a year-over-year revenue growth of 93.9%. The company has not yet achieved profitability, with an earnings per share (EPS) of -$0.97. The next earnings report is expected on November 3, 2026.
Insider Buying and Selling at ImmunityBio, Inc.
Several insiders have been active in the market. On June 24, 2026, Barry Simon sold 25,000 shares at an average price of $7.88, totaling $197,000. Director Christobel E. Selecky sold 96,722 shares on June 30, 2026, valued at $871,216. On July 1, 2026, Selecky sold an additional 159,478 shares at $9.02, bringing her total sale value to approximately $1.4 million. Another director, Cheryl L. Cohen, sold 131,210 shares at $9.50 on July 2, 2026, totaling about $1.2 million.
Analysts Set New Price Targets
On October 15, 2026, Jefferies maintained a Buy rating on ImmunityBio with a price target of $14.00, up from a prior target of $12.00. HC Wainwright & Co. also reiterated a Buy rating with a price target of $15.00, unchanged from previous estimates. The consensus among analysts is a strong Buy, with a mean price target of $14.25 based on four analyst opinions.
About ImmunityBio, Inc.
ImmunityBio, Inc. is a biotechnology company based in San Diego, CA. It specializes in creating innovative immunotherapies aimed at activating patients' immune systems to fight cancer and infectious diseases. The company's focus on next-generation treatments makes it a significant player in the healthcare sector.
Bottom Line
Investors will be watching for ImmunityBio's next earnings report on November 3, 2026, as well as any further trades from insiders. McClain's recent purchase adds to her previous investments in various companies, indicating her continued interest in the biotechnology sector.
Related Filing Alerts
Source: Lisa C. McClain's STOCK Act disclosure on $IBRX (Sep 30, 2026). Read the original filing: STOCK Act disclosure (House Clerk). Written by software, not financial advice. How we make alerts